Read this as a labeled formula, not live inventory
The record identifies Refissa as tretinoin 0.05% in an emollient water-in-oil cream. Its listed base includes mineral oil, sorbitol solution, dimethicone and other inactive ingredients. That formulation detail is useful for discussing texture or ingredient history, but emollient does not mean irritation-free or appropriate for every dry-skin concern.
There is a practical reason to keep the record date visible. Older package listings, distributor names and ingredient records can remain searchable after commercial arrangements change. An inactivated package code is not, by itself, a finding that a drug was withdrawn for a safety problem. It also cannot establish that a currently advertised tube is authentic or available.
If a pharmacy offers a product under this name, ask for its current manufacturer or distributor, package identifier, labeling and usable date. The online-pharmacy guide explains how to identify the dispenser. This review does not recommend seeking out old stock or treating an archived record as authorization to buy without a prescription.
The indication includes a skin-care program
The reviewed label describes Refissa as an additional treatment for fine wrinkles, mottled hyperpigmentation and tactile roughness of facial skin when a comprehensive skin-care and sun-avoidance program has not provided the desired improvement. The word additional matters: the clinical context includes protective clothing, sunscreen and emollient care, not a cream used in isolation.
The label does not claim to remove wrinkles, reverse photoaging or restore a younger microscopic skin pattern. It also distinguishes the listed concerns from deep wrinkles, skin laxity and other changes for which a mitigating effect was not demonstrated. That prevents a familiar category error: turning an effect on one graded feature into a promise to repair everything described as sun damage.
Mottled pigmentation in this indication should not become permission to apply a prescription to any dark area. A new, changing or unexplained lesion needs assessment on its own terms. The clinician must establish what is being treated before the product's labeled purpose can be meaningfully compared with that concern.
What the controlled evidence reports
The label presents two controlled trials with 161 evaluable patients receiving tretinoin emollient cream 0.05% and 154 receiving vehicle cream, alongside comprehensive care for twenty-four weeks. Participants in that efficacy analysis were under fifty. The outcomes were assessed on a rating scale rather than by counting years removed from a person's appearance.
For fine wrinkling, 24% in the active-cream group achieved the label's moderate-improvement category, compared with 8% in the vehicle group. Minimal improvement was reported in 40% and 30%, respectively. Those categories represent changes on the study scale; neither is a universal definition of a dramatic visible result.
The control group is worth reading carefully. Improvement with vehicle plus skin care shows why a before-and-after photograph cannot identify how much change was attributable to tretinoin alone. The guide to photographic reviews explores lighting, accompanying care and selection effects that make isolated images hard to interpret.
Population and duration limits remain visible
The label states that effectiveness for these purposes was not established in people over fifty or in people with moderately to heavily pigmented skin. It also notes exclusions for visible actinic keratoses and a history of skin cancer. These are significant limits for a product often discussed in an aging-skin context.
They do not prove that every person outside the studied population would receive no benefit. They do prevent this review from making a confident claim about their response using these trial results. A clinician may consider a broader evidence base and the individual situation, but that reasoning should not be replaced by a reviewer's extrapolation.
The label also limits what was established about daily use beyond forty-eight weeks. That is an evidence boundary, not a personal instruction to stop on a particular date or restart after a break. Our mature-skin consultation guide helps keep the treatment goal, medical history and follow-up arrangement in the same conversation.
An emollient base does not remove precautions
The reviewed information describes peeling, dryness, stinging, burning and redness among local reactions. It reports that 4% of patients in the described vehicle-controlled safety studies discontinued because of adverse reactions. That percentage belongs to those studies; it should not be treated as a risk estimate for every current tretinoin preparation.
Pregnancy-related restrictions, sunlight sensitivity, eczema and other facial skin conditions are addressed in the label. So are medicines that can increase sensitivity to light. Those details make a full medication and skin-product list important, including items obtained without a prescription. They do not support choosing an application schedule from this article.
A cream can feel rich while still provoking irritation. The inactive-ingredient guide explains why the base deserves review when discussing a previous reaction. A reaction also cannot be diagnosed as permanent thinning by its feel alone; our skin-thickness evidence guide separates that concern from the measurements made in studies.
What would make an actual offer assessable
A current written quote would need the exact product, quantity, full price, pharmacy and any consultation fee. The label's package information does not supply those answers. We therefore do not assign a monthly Refissa cost, make a current savings claim or add an unverified price to the comparison tool.
A prescriber should also explain why the proposed product fits the concern, what alternatives are relevant and how questions or reactions will be handled. A similar percentage on Retin-A cream or another preparation does not erase differences in indication, vehicle and supporting record. Likewise, a compound containing tretinoin does not inherit this product's regulatory history.
The useful conclusion is limited but concrete: Refissa's public record documents a particular emollient formula and a bounded evidence base. Anyone considering a present-day offer still needs current dispensing information and a clinical decision. Keeping that gap explicit is more useful than presenting an old product name as a newly verified source of treatment.